June 6, 2018 11:55 AM EDT

Biogen, Eisai BACE drug cuts amyloid beta in the brain, but there’s no hard data to show it does anything important for cognition

John Carroll

Editor & Founder

Just after Merck $MRK research raised serious doubts about the BACE approach to tackling Alzheimer’s disease, researchers for Biogen $BIIB and Eisai are fighting …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biogen, Eisai BACE drug cuts amyloid beta in the brain, but there’s no hard data to show it does anything important for cognition

John Carroll

Editor & Founder

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Amgen names Stanford geneticist and biotech founder to CSO post

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Caltech spinout debuts with AI-driven 'mirror peptide' platform

Are programs with compounded GLP-1s safe for your population?

Bio­gen, Ei­sai BACE drug cuts amy­loid be­ta in the brain, but there’s no hard da­ta to show it does any­thing im­por­tant for cog­ni­tion

John Carroll

Editor & Founder

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Biogen, Eisai BACE drug cuts amyloid beta in the brain, but there’s no hard data to show it does anything important for cognition

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Amgen names Stanford geneticist and biotech founder to CSO post

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Caltech spinout debuts with AI-driven 'mirror peptide' platform

Are programs with compounded GLP-1s safe for your population?